Biopharma leader with 15+ years of oncology research and 8+ years directing cell & gene therapy (CGT) GMP manufacturing and CMC programs. Expert in strategic project leadership, IND-enabling documentation, regulatory compliance (FDA/ICH), and CDMO partnerships. Proven track record delivering plasmid, mRNA, viral vector, CAR-T, and TCR-T therapies through Phase I/II clinical milestones. Recognized for cross-functional leadership, client engagement, and risk-managed execution of multimillion-dollar GMP programs.
Overview
15
15
years of professional experience
1
1
Certification
Work History
Principal Scientist / Development Scientist III, Project Lead
Leidos Biomedical Research, Inc.
09.2021 - Current
Directed 8+ concurrent GMP programs (plasmid, mRNA, viral vectors, CAR-T, TCR-T), managing timelines, resources, and deliverables using MS Project and Smartsheet.
Led end-to-end program execution from process development through GMP manufacturing, ensuring alignment with CMC milestones.
Delivered 12+ clinical trial products on schedule, supporting client development budgets exceeding $10M.
Coordinated across QA, QC, RA, Manufacturing, Finance, and Business Development to achieve project goals.
Represented project progress in executive reviews and client meetings, ensuring transparency, alignment, and confidence in program delivery.
Simplified complex scientific processes (gene editing, viral vectors) for diverse stakeholders.
Reviewed and approved batch records, assay specs, and COAs, ensuring quality compliance.
Acted as supply chain SME, accelerating procurement of GMP-grade raw materials through vendor negotiations.
Optimized project management infrastructure by introducing standardized trackers, SOPs, and documentation systems.
Built and scaled automated GMP processes (Prodigy, G-Rex), improving efficiency, scalability, and cost-effectiveness.
Strategic Project Leadership
Operational Oversight & Continuous Improvement
Senior Scientist / Process Development Scientist II
Leidos Biomedical Research, Inc.
01.2017 - 08.2021
Developed autologous and allogeneic CGT platforms including AAV, VLPs, and chimeric antibodies.
Optimized AAV9-DMD and AAV2-AADC production platforms; contributed to FDA approval of AAV2-AADC (Kebildi).
Authored CMC Module 3 documentation, QC protocols, COAs, and supported IND submissions.